Business Wire

1936 Bugatti Type 57SC Coupé Atlantic Wins Third Annual The Peninsula Classics Best of the Best Award

Del

A rare and beautiful 1936 Bugatti Type 57SC Atlantic was named the winner of the prestigious The Peninsula Classics Best of the Best Award today at The Peninsula Paris hotel.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180208006584/en/

(Photo: Business Wire)

(Photo: Business Wire)

Now in its third year, The Peninsula Classics Best of the Best Award brought together eight of the world’s finest classic cars—the best of show winners from the top international concours—to compete for the title of the most exceptional motor car in the world. The Bugatti is co-owned by the Mullin Automotive Museum, and Rob and Melani Walton, located in California, USA, and was named “Best of Show Concours d’Etat” at the 2017 Chantilly Arts & Elegance.

Speaking of the award’s legacy, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited and co-founder of the award said, “My great hope is that we not only succeed in thrilling long-term car enthusiasts, but that this award will also ignite a new-found passion for those just discovering the world of motoring.”

Powered by a supercharged engine and considered by many to be the first supercar ever made, the winning Bugatti is one of four Type 57 Atlantic models ever produced, with only three in the world remaining. The vehicle was designed at the height of the art deco movement by Jean Bugatti, Ettore Bugatti’s son. Jean based the car on his other design, the 1935 Aérolithe concept car, which was famously riveted externally, for fear of the magnesium-alloy body parts catching fire. Jean kept this signature riveted seam on the all-aluminium body of the Atlantic.

“The Bugatti Type 57SC Atlantic is the crown jewel of the automotive circuit,” said Bugatti Head of Tradition Julius Kruta. “This car was Jean Bugatti’s masterpiece with its beautiful and breath-taking lines, plus its unmatched performance for the time. Today, it remains the ultimate expression of the Bugatti legacy: unparalleled power and beautiful design.”

This model, chassis number 57374, was the first Type 57 Atlantic produced and is the only surviving “Aéro Coupé,” a designation given to the first two cars that were mechanically very similar to the Aérolithe. The car was delivered new in 1936 to Britain’s Nathaniel Mayer Victor Rothschild, third Baron Rothschild, and has since passed through few owners in its 82-year history. The car has been displayed internationally, and most recently, was on display at the Los Angeles-based Petersen Automotive Museum for the “Art of Bugatti” exhibit.

“The Atlantic represents the pinnacle of everything I adore about French automotive styling and is widely described as the Mona Lisa of the automobile collector world,” said Peter Mullin, Founder and CEO of the Mullin Automotive Museum. “From its signature curves to its aviation-inspired rivets, to the Jean Bugatti designed sleek all-aluminium body, the car is truly a remarkable piece of art. I’m very honoured to have shared it with the world amongst other worthy ‘Best of the Best’ contenders.”

“I second Peter’s thoughts – the other seven nominees were simply stunning, which makes winning the award feel even more special,” said Rob Walton, co-owner of the winning car. “What this award does is allow us to take a step back and admire the quality and beauty of the greatest classic cars in existence today. For an automotive fan like myself, it’s a joy.”

The founders of The Peninsula Classics Best of the Best Award are each known as some of the world’s foremost motoring experts, and were brought together by their shared passion for fine motor vehicles, impeccable restorations, as well as the preservation of tradition and heritage.

The Hon. Sir Michael Kadoorie, together with award co-founders Christian Philippsen, William E. “Chip” Connor and Bruce Meyer, created the award. The gentleman each cite a passion for automotive excellence as the inspiration behind the creation of The Peninsula Classics Best of the Best Award .

According to Bruce Meyer, “For the third year, the ultimate standard for judging  The Peninsula Classics Best of the Best Award  was that of uncompromised quality and design. Of course, this made the selection process most challenging for the esteemed group of panellists.” He continued: “In the end, the 1936 Bugatti Type 57 SC Coupé Atlantic emerged victorious, with its exceptional, bespoke design making it a marvellous combination of art and technology.”

Previously presented during Monterey Car Week, the award moved to Paris this year to be presented during the world-famous Rétromobile event. The Bugatti was presented at an exclusive reveal party in The Peninsula Paris’ subterranean garage, following a private dinner.

The winning vehicle was selected after being reviewed by 24 automotive experts, designers and notable celebrities within the motoring world. Learn more about each judge, in addition to the seven other nominees by clicking here.

The Peninsula Hotels, owned and operated by The Hongkong and Shanghai Hotels, Limited, is proud to sponsor The Peninsula Classics Best of the Best Award , a natural extension of the group’s passion and appreciation for luxury, travel and the motoring lifestyle. With 10 hotels in global gateway cities throughout Asia, USA and Europe, The Peninsula Hotels celebrates glamour in travel, and aims to showcase the ultimate in sophistication, innovation and design. Known for its timelessly elegant hotels, discreet integration of technology and functionality, and extensive fleet of luxury transport, the group aims to bring its heritage and expertise to celebrate the very best in the world of motoring.

For more information, please visit http://peninsula.com/bestofthebest.

About The Peninsula Classics Best of the Best Award

The Peninsula Classics Best of the Best Award is among the top automotive awards in the world. In its milestone development of the international motoring world’s top accolade for most exceptional classic car, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited, launched the award in 2015 with co-founders Christian Philippsen, William E. “Chip” Connor and Bruce Meyer to celebrate the best of what defines the automotive world. Each founder shares a common passion and appreciation of fine motor cars, the preservation of their heritage and immaculate restoration projects. The award, sponsored by The Peninsula Hotels, brings together eight of the concours circuits’ elite best of show winners from around the globe.

http://signatureevents.peninsula.com.

Contact information

Media:
JMPR Public Relations
Sanaz Marbley/Elana Cates, 818-992-4353
smarbley@jmprpublicrelations.com
ecates@jmprpublicrelations.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch